Skip to content

MAPharm OÜ

Registry code (registrikood) 14292621Private limited company (Osaühing)VAT EE102038190Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€4.2M
▲ 3.9% vs 2024
Profit before tax (2025)
-€266k
Employees, FTE (2025)
17
State taxes paid, last 4 quarters
€342k

Revenue, profit and employees, 2019–2025

€1.1M2019€1.9M2020€2.2M2021€2.5M2022€3.2M2023€4.0M2024€4.2M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€1,103,019-€87,143-€89,373-€174,4399
2020€1,913,331-€50,511-€54,211-€228,65011
2021€2,249,721€59,154€55,770-€172,88014
2022€2,536,605€108,443€105,216-€67,66412
2023€3,166,227-€123,938-€126,720-€194,38419
2024€4,017,894€43,838€41,047-€153,33716
2025€4,174,860-€262,948-€265,732-€419,06917

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€24,838€390,186€518,125€46,500-€174,439
2020€22,026€392,704€574,854€46,500-€228,650
2021€72,156€412,716€539,096€46,500-€172,880
2022€76,709€505,893€527,057€46,500-€67,664
2023€143,249€797,866€945,750€46,500-€194,384
2024€80,712€1,128,645€1,235,482€46,500-€153,337
2025€56,393€764,873€1,137,442€46,500-€419,069

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€52,243€40,169€645,44115
2022 Q2€50,226€40,441€698,99214
2022 Q3€53,098€44,034€646,38114
2022 Q4€50,876€39,229€667,20513
2023 Q1€70,215€39,383€775,74313
2023 Q2€45,310€41,358€745,00314
2023 Q3€44,840€43,568€757,05918
2023 Q4€52,615€48,917€1,001,61621
2024 Q1€65,067€60,871€965,66620
2024 Q2€71,784€64,845€1,077,82322
2024 Q3€71,389€67,186€950,52423
2024 Q4€58,552€57,069€982,67724
2025 Q1€141,505€69,862€1,414,45921
2025 Q2€73,661€73,185€1,027,62721
2025 Q3€86,537€77,224€1,065,56421
2025 Q4€84,707€72,780€1,190,55222
2026 Q1€85,325€70,207€1,295,63322
2026 Q2€73,112€74,325€1,198,34125
2026 Q3€98,654€88,706€1,533,79523

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), MAPharm OÜ reported revenue of €4,174,860.

The company recorded a net loss of €265,732 in the 2025 financial year.

Revenue increased by 3.9% from €4,017,894 in 2024 to €4,174,860 in 2025.

Revenue grew at a compound annual rate of 24.8% between 2019 and 2025.

Equity accounted for -54.8% of total assets of €764,873 at the end of the 2025 reporting period.

With 17 full-time-equivalent employees in 2025, revenue per employee was €245,580.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, MAPharm OÜ reported €5,218,321 in turnover.

EMTA recorded 23 employees for the quarter ending Q3 2026, compared with 17 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.